In silico identification of linear B-cell epitope in Coronavirus 2019 (SARS-CoV-2) surface glycoprotein: a prospective towards peptide vaccine
Minerva Biotecnologica
; 33(1):29, 2021.
Article
in English
| ProQuest Central | ID: covidwho-1192456
ABSTRACT
BACKGROUND:
The 2020 Coronavirus pandemic continuing spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). At the moment, there is no specific antiviral treatment or monoclonal antibodies or vaccines available for COVID-19. SARS-CoV-2 is positive-stranded RNA viruses with a crown-like appearance due to the occurrence of spike (surface) glycoproteins on the envelope. In the present study, the computational method used to predict the significant linear B cell epitopes of SARS-CoV-2 surface glycoprotein.METHODS:
FASTA sequence of SARS-CoV-2 surface glycoprotein was retrieved from the NCBI database, and further its primary and secondary structure was analyzed for its physical and chemicals properties. IEDB server was used to predict the B-cell epitopes.RESULTS:
ABCprep server and IEDB server prediction results for B-cell epitopes showed 16 and 21 linear epitope sequences respectively in the surface glycoprotein of SARS-CoV-2.CONCLUSIONS:
Obtained results conclude that predicted B-cell Epitopes may serve as an immunogen for eliciting monoclonal antibodies which can be used as a potential candidate for the treatment or diagnostic purpose for COVID-19.
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
Minerva Biotecnologica
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS